Abaloparatide (Tymlos) vs LL-37
Updated October 16, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of Abaloparatide (Tymlos) and LL-37 (also searched as LL-37 vs Abaloparatide (Tymlos)) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
Abaloparatide (Tymlos) centers on healing, while LL-37 leans toward healing. On indexed research, LL-37 is ahead (Abaloparatide (Tymlos): 34 studies, Human clinical; LL-37: 35, Human evidence). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •Abaloparatide (Tymlos) is strongest for healing; LL-37 for healing.
- •Evidence: Abaloparatide (Tymlos) Human clinical (34 studies) vs LL-37 Human evidence (35).
- •Check the FDA-approval status chips above before assuming a legal use pathway.
Effect profiles, overlaid
At a glance
PTH1R Activation | Osteoporosis Treatment
Abaloparatide (Tymlos) vs LL-37: side-by-side
| Metric | Abaloparatide (Tymlos) | LL-37 |
|---|---|---|
| Class | Healing | Immune |
| Regulatory status | FDA-approved | Research use only |
| Evidence grade | Human clinical | Human evidence |
| Studies indexed | 34 | 35 |
| Research level | FDA Approved | Well Studied |
| Strongest effect | Healing & recovery | Healing & recovery |
| Healing & recovery | 4.0 | 5.0▲ |
| Muscle & body comp | 1.0▲ | 0.0 |
| Metabolic & appetite | 2.0▲ | 0.0 |
| Neuro & mood | 0.0 | 0.0 |
| Sleep & circadian | 0.0 | 0.0 |
| Inflammation & immune | 1.0 | 4.0▲ |
| Skin & aesthetics | 0.0 | 2.0▲ |
▲ marks the higher AI-assigned effect score (0–5, describing where the literature concentrates — not clinical efficacy).
Mechanism & pharmacokinetics
| Property | Abaloparatide (Tymlos) | LL-37 |
|---|---|---|
| Mechanism | PTH1R agonist | Disrupts microbial membranes, modulates immune responses |
| Route | Subcutaneous injection | — |
| Half-life | ~30 min | — |
| Time to peak | 4 hours | — |
| Duration of action | 24 hours | — |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is Abaloparatide (Tymlos)?
Abaloparatide (Tymlos) is a synthetic PTHrP analog and FDA-approved anabolic agent for osteoporosis, building bone via selective PTH1R activation.
Full Abaloparatide (Tymlos) profile, mechanism & studies →What is LL-37?
LL-37 is a human cathelicidin antimicrobial peptide that plays a crucial role in the innate immune response. It is produced by various cells, including epithelial cells and neutrophils, and exhibits a broad spectrum of biological activities, including antimicrobial, immunomodulatory, and wound healing properties. LL-37 interacts with a variety of pathogens, including bacteria, viruses, and fungi, contributing to the host's defense mechanisms.
Full LL-37 profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | LL-37 | 5.0/5 effect signal |
| Muscle | Abaloparatide (Tymlos) | 1.0/5 effect signal |
| Metabolic | Abaloparatide (Tymlos) | 2.0/5 effect signal |
| Inflammation | LL-37 | 4.0/5 effect signal |
| Skin | LL-37 | 2.0/5 effect signal |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack Abaloparatide (Tymlos) and LL-37?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because at least one is a research-use compound, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
Abaloparatide (Tymlos) vs LL-37: side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
Abaloparatide (Tymlos) has 34 approved studies indexed (Human clinical), and LL-37 has 35 (Human evidence). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is Abaloparatide (Tymlos) or LL-37 better?
It depends on your goal. Abaloparatide (Tymlos) is strongest for healing; LL-37 for healing. LL-37 has more indexed studies (35). See the goal-by-goal breakdown above.
Is Abaloparatide (Tymlos) or LL-37 better for weight loss?
Abaloparatide (Tymlos) shows the stronger metabolic & appetite profile (2.0/5) in the AI-assigned effect profile — though weight-loss outcomes depend on the individual and the evidence base.
Is Abaloparatide (Tymlos) or LL-37 better for muscle?
Abaloparatide (Tymlos) leads on the muscle & body-composition axis (1.0/5).
Which has more research, Abaloparatide (Tymlos) or LL-37?
Abaloparatide (Tymlos) has 34 approved studies indexed (Human clinical); LL-37 has 35 (Human evidence). Higher counts mean more to read, not proven superiority.
Can you stack Abaloparatide (Tymlos) and LL-37?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of Abaloparatide (Tymlos) vs LL-37?
Abaloparatide (Tymlos): no community-reported effects logged yet. LL-37: none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is Abaloparatide (Tymlos) or LL-37 FDA-approved?
Abaloparatide (Tymlos) is FDA-approved. LL-37 is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is LL-37 better than Abaloparatide (Tymlos)?
For healing, LL-37 has the edge; for healing, Abaloparatide (Tymlos) does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
Approval status varies (see the chips at the top). FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed October 16, 2026.